EUVIMEDEUVIMED entdecken
Crossref

Ru(II)-Photodynamic Therapy Suppresses Nonfunctioning Pituitary Adenoma Growth by Targeting PI3K/AKT/p53 Signaling

Dong Fan, Zhongyu Wang, Xingyi Yuan, Shixue Luo, Runsi Zhan, Weiyu Hu, Huitong Chen, Weiwen Wang, Jing Liu, Zongming Wang, Xin Wang iD

ACS Applied Bio Materials · 2025

DOI: 10.1021/acsabm.5c01123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Bio Materials, 2025. Verfasst von Dong Fan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Affiliated Hospital, Guangdong Pharmaceutical University, Guangzhou 510699, China. Hauptthemen laut MEDLINE: Photochemotherapy, Pituitary Neoplasms, Ruthenium, Photosensitizing Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: China National Funds for Distinguished Young Scientists, Guangdong Medical Research Foundation, Traditional Chinese Medicine Bureau of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims Nonfunctioning pituitary adenomas (NFPAs) are a common intracranial tumor in clinical practice, and currently available treatments for NFPA include surgical resection and radiotherapy. However, this is due to the relatively high risk of recurrence and persistent side effects of these therapies. As a local treatment, photodynamic therapy (PDT) shows promise in solid tumors through spatiotemporally controlled cytotoxicity. The aim of this study was to investigate the mechanism of action of photosensitizer Ru2 in NFPA. Materials and methods [Ru(tpy)(tpy-Br)] (PF6)2 was synthesized from Ru(tpy)Cl3, and further synthesized into Ru2. Cell viability of Light+Ru2 or Dark+Ru2 was assayed using the CCK-8 assay and live-dead cell staining. RNA-seq of Light+Ru2-treated PDFS cells yielded differentially expressed genes. The expression of PI3K/ATK/P53 was detected using qPCR, Western blot. PI3K agonist 740Y-P and AKT agonist SC79 were added for further pathway validation. The effect of PDT on PDFS cell viability by 3D multicellular tumor spheroids (MCTSs) was evaluated. Key findings We untangle that Ru2-PDT specifically activates the p53 pathway and inhibits PI3K/AKT phosphorylation in PDFS cells. Under 595 nm illumination, Ru2 activates p53 and induces cell cycle arrest in the G0/G1 phase. Simultaneously, Ru2-PDT significantly suppressed the phosphorylation of the PI3K/AKT signaling pathway. Further investigation reveals that the PI3K/AKT agonist treatment partially inhibits p53 expression, alleviates Ru2-PDT-induced apoptosis, and reverses its inhibitory effects on PDFS cell migration and invasion. Significance This study, for the first time, elucidates the molecular mechanism of Ru2-PDT targeting the PI3K/AKT/p53 signaling axis, providing a theoretical basis for the clinical treatment of nonfunctioning pituitary adenomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhotochemotherapyPituitary NeoplasmsRutheniumPhotosensitizing AgentsAntineoplastic AgentsAdenomaHumansProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesTumor Suppressor Protein p53Signal TransductionDrug Screening Assays, AntitumorCell ProliferationCell SurvivalDose-Response Relationship, DrugCell Line, TumorMolecular StructureApoptosis

Stichwörter der Autor:innen

NFPAPDTPI3K/AKTapoptosisterpyridyl Ru (II) complex

Substanzen

Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesTumor Suppressor Protein p53RutheniumPhotosensitizing AgentsAntineoplastic AgentsTP53 protein, human

Autor:innen und Institutionen

  • Department of Neurosurgery, The First Affiliated Hospital, Guangdong Pharmaceutical University, Guangzhou 510699, China.
  • School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, China.
  • Department of Neurosurgery, Pituitary Tumor Center, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.

ORCID-Profile: Xin Wang

Förderung

  • China National Funds for Distinguished Young Scientists
  • Guangdong Medical Research Foundation
  • Traditional Chinese Medicine Bureau of Guangdong Province
  • Key Clinical Technique of Guangzhou
  • Guangdong Medical Association Clinical Research Special Fund

Zitieren

APA

Fan, D., Wang, Z., Yuan, X., Luo, S., Zhan, R., Hu, W., Chen, H., Wang, W., Liu, J., Wang, Z., & Wang, X. (2025). Ru(II)-Photodynamic Therapy Suppresses Nonfunctioning Pituitary Adenoma Growth by Targeting PI3K/AKT/p53 Signaling. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.5c01123

Vancouver

Fan D, Wang Z, Yuan X, Luo S, Zhan R, Hu W, et al. Ru(II)-Photodynamic Therapy Suppresses Nonfunctioning Pituitary Adenoma Growth by Targeting PI3K/AKT/p53 Signaling. ACS Applied Bio Materials. 2025. doi:10.1021/acsabm.5c01123

BibTeX
@article{Fan2025,
  author = {Fan, Dong and Wang, Zhongyu and Yuan, Xingyi and Luo, Shixue and Zhan, Runsi and Hu, Weiyu and Chen, Huitong and Wang, Weiwen and Liu, Jing and Wang, Zongming and Wang, Xin},
  title = {Ru(II)-Photodynamic Therapy Suppresses Nonfunctioning Pituitary Adenoma Growth by Targeting PI3K/AKT/p53 Signaling},
  journal = {ACS Applied Bio Materials},
  year = {2025},
  doi = {10.1021/acsabm.5c01123}
}
Kostenlos starten →